Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Study of Sofosbuvir/Velpatasvir for 12 Weeks in Chronic Hepatitis C Virus Infection
2015-003001-42Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sofosbuvir and velpatasvir in chronic hepatitis C (CHC) and hepatitis C virus infection, sponsored by Gilead Sciences. Primary endpoints: Sustained virologic response at 12 weeks after treatment (SVR12), Sustained virologic response at 4 weeks after treatment (SVR4) and 1 more. Started Oct 2015; status: completed.
02
Drugs
sofosbuvirvelpatasvir
03
Conditions
chronic hepatitis C (CHC)hepatitis C virus infection
Beyond the preview
Go deeper on 2015-003001-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003001-42.